Evaxion Biotech A/S (NASDAQ:EVAX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $14.00 price target on the stock.

Evaxion Biotech A/S Trading Up 1.9 %

Shares of EVAX opened at $2.64 on Friday. Evaxion Biotech A/S has a 1 year low of $2.26 and a 1 year high of $13.61. The stock’s 50-day moving average price is $2.95 and its two-hundred day moving average price is $3.18. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to the consensus estimate of $0.19 million. Equities analysts expect that Evaxion Biotech A/S will post -0.24 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned approximately 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.